Here are my dots from the 10Q...
Dot #1
In October 2016, upon review of these findings, the Company announced early closure of GOG-0265. Based on these data, the Company plans on pursuing regulatory opportunities for this unmet medical need in Europe in 2017, and is planning to initiate a Phase 3 registrational trial in 2017 in the metastatic cervical cancer setting. Results from the GOG-0265 study will be presented at the Society of Gynecologic Oncology (“SGO”) meeting on March 14, 2017 and was selected for an oral late-breaker presentation...IMO, late beaking means phenomenal success and thus the note above regarding EU submission.
Dot #2
Laboratory costs were $1,269,731 for the three months ended January 31, 2017 compared to $251,688 for the three months ended January 31, 2016, an increase of $1,018,043. An increase in headcount and the expansion of laboratory space accounted for the increase...Gearing up for commercial production?
Dot #3
Other expenses were $333,303 for the three months ended January 31, 2017 compared to $144,218 for the three months ended January 31, 2016, an increase of $189,085. The increase was due to additional infrastructure costs incurred to support the increased headcount and laboratory expansion....Why increased headcount if just for trial related activities? The job descriptions for the new positions have a commercialzation flair to it.
Dot #4
We anticipate a significant increase in research and development expenses as a result of our intended expanded development and commercialization efforts primarily related to clinical trials and product development. In addition, we expect to incur expenses in the development of strategic and other relationships required to license, manufacture and distribute our product candidates when they are approved...Did I say commercialization?
If we do obtain EU approval, I certainly hope the POTUS does allow money held outside the U.S. to come back in. If by chance we can't bring it back(without stiff fees), then there may be a need to dilute further to continue our aggressive agenda (assuming no domestic partners).
Perhaps the powers to be have come to the same conclusion and thus did everything they could to beat the share price down in order to accumulate on the cheap.
If we do obtain EU approval, then our share price should reflect U.S. approval as well since it is just a matter of time.
BTW, What is the potential for this market?
These are just my thoughts and opinion so please draw your conclusions.
